Kymera Therapeutics Inc
(NAS:KYMR)
$
31.12
-0.7 (-2.2%)
Market Cap: 1.91 Bil
Enterprise Value: 1.52 Bil
PE Ratio: 0
PB Ratio: 2.69
GF Score: 60/100 - Q1 2024 Kymera Therapeutics Inc Earnings Call TranscriptMay 02, 2024$36.3 (+0.17%)Earnings
- Q4 2023 Kymera Therapeutics Inc Earnings Call TranscriptFeb 22, 2024$40.49 (+4.71%)Earnings
- Kymera Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Kymera Therapeutics Inc Virtual Immunology R&D Day TranscriptJan 04, 2024
- Kymera Therapeutics Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- Q3 2023 Kymera Therapeutics Inc Earnings Call TranscriptNov 02, 2023$12.08 (+4.59%)Earnings
- Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Kymera Therapeutics Inc Earnings Call TranscriptAug 03, 2023$23.88 (+11.07%)Earnings
- Kymera Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Kymera Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Kymera Therapeutics Inc Earnings Call TranscriptMay 04, 2023$26.24 (-15.08%)Earnings
- Q4 2022 Kymera Therapeutics Inc Earnings Call TranscriptFeb 23, 2023$33.16 (+5.17%)Earnings
- Kymera Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Kymera Therapeutics Inc Investor Webcast KT-474 Clinical Update Call TranscriptDec 14, 2022
- Kymera Therapeutics Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Kymera Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Q3 2022 Kymera Therapeutics Inc Earnings Call TranscriptNov 03, 2022$30.92 (+7.55%)Earnings
- Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Q2 2022 Kymera Therapeutics Inc Earnings Call TranscriptAug 09, 2022$30.35 (-3.44%)Earnings
- Kymera Therapeutics Inc at UBS Global Healthcare Conference TranscriptMay 23, 2022
- Kymera Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Kymera Therapeutics Inc Earnings Call TranscriptMay 03, 2022$24.88 (-23.98%)Earnings
- Kymera Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Kymera Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Kymera Therapeutics Inc To Host Virtual R&D Day TranscriptDec 16, 2021
- Kymera Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference TranscriptDec 01, 2021
- Kymera Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2021
- Kymera Therapeutics Inc To Discuss Data From KT-474 Phase 1 Trial Call TranscriptOct 27, 2021
- Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Kymera Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Kymera Therapeutics Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Kymera Therapeutics Inc Presenting at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Kymera Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 08:15PM GMT
Release Date Price:
$18.99
(-0.47%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
All right. Welcome, everyone. This is the fireside chat with Kymera Therapeutics. My name is Vikram Purohit. I'm one of the biotech analysts with the Morgan Stanley research team. Before we get started, I need to read a brief disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please see -- please reach out, excuse me, to your Morgan Stanley sales representative.
With that, very happy to have with me Nello and Jared from the Kymera team. Thank you both for joining us.
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thank you.
Jared A. Gollob;Vikram Purohit
Kymera Therapeutics, Inc. - Chief Medical Officer;Morgan Stanley, Research
Yes. Thanks, Vikram.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)